Antibodies Market

Market Insights on Antibodies covering sales outlook, demand forecast & up-to-date key trends

Antibodies Market by Disease Indication (Cardiovascular diseases, CNS disorders, Cancer, Autoimmune Disorders), Product Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs)), End User & Region - Forecast to 2021-2031

Request Sample Talk to Analyst

Antibodies Market Snapshot

Antibodies Market will grow by 21x in upcoming decade, surpassing US$ 601.614 Billion by the end of 2031, finds Future Market Insights (FMI).

North America is anticipated to dominate the Antibodies Market holding around 45.8% of the overall market share in 2021. The growth can be attributed to rising awareness, increasing government funding to find treatment for chronic ailments and presence of leading market players in U.S. and Canada.

FMI also states that, F. Hoffmann-La Roche Ltd., AbbVie Inc., Johnson & Johnson Services, Inc., Amgen Inc., and Bristol-Myers Squibb Company are leading players operating in the antibodies market. Collectively they will account for 3 out of 4 sales of antibodies across the globe.

Customize this Report

Let us know your requirement to get
100% FREE customization

Customize Now

Antibodies Market - Key Points Covered in Study

Antibodies Market estimates and forecast 2021 – 2031
Key drivers and restrains impacting Antibodies Market growth
Segment-wise, Country-wise, and Region-wise Analysis
Competitive Mapping and Benchmarking
Brand share and Market Share Analysis
Key Product Innovations and Regulatory Climate
COVID-19 Impact On Antibodies Market and How to Navigate
Recommendation on Key Winning Strategies

Antibodies Market Outlook In Comparison to 2021 – 2031 Forecast

Antibodies are essential for treating medical conditions like autoimmune diseases, cancer, and various type neurological diseases. Certain type of antibodies called immunoglobulin (IG) is used for the prevention of lower respiratory tract infections and diseases caused by vaccinia virus. Rising cases of viral infection will drive the demand for antibodies.

National Stem Cell Foundation (NSCF) has reported that about 4% of global population is affected by some kind of autoimmune diseases. The most common autoimmune diseases are diabetes, multiple sclerosis, Crohn’s disease and rheumatoid arthritis.

Autoimmune diseases also act as a host for multiple chronic ailments. As the prevalence of autoimmune diseases is on the rise, the demand for antibodies is forecast to increase in upcoming years.

In April 2021, Xencor commenced its Phase I clinical trial of its new engineered Interleukin-2 (IL-2) Fc cytokine and XmAb564 antibody therapeutics designed for developing treatment of patients with autoimmune diseases.

The COVID-19 pandemic boosted the demand for antibodies as patients suffering from COVID-19 were highly susceptible to contracting various other ailments and in some cases triggered the autoimmune diseases in the patient.

Zydus Cadila is planning to launch its own antibody cocktail, ZRC-3308, through trials in India. The antibody cocktails are used in COVID-19 patients who are at risk of progressing to severe disease.

Novel biosimilar antibodies manufacturers are slashing their prices to compete with branded antibodies manufacturers especially in European market. With expiration of patents of renowned products, a boost in demand for biosimilar antibodies can be expected in upcoming years.

Antibodies Market Download Report Brochure

How do Research and Development Activities Impact Antibodies Sales Outlook?

Surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies and biosimilar antibodies are driving the market growth.

In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services.

In September 2020, Regeneron collaborated with Roche for efficient clinical trials of their monoclonal antibody treatment (REGN-COV2) for COVID-19.

Rising cases of multiple sclerosis and Parkinson’s disease among older population is key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, and novel and effective treatments in middle income countries. This is expected to positively influence the sales of antibodies.

In 2021, Berkeley Lights, a digital cell biology company joined hands with Genovac, an antibody discovery company to readily access the right antibodies in the shortest amount of time with the help of modern technology.

Considering this, the rising application of antibodies in chronic diseases treatment will create scope for market expansion in the near future.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How Is Increasing Production of Bio-similar Antibodies driving Demand?

Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies and they have very few side effects.

In 2020, Johnson and Johnson reported US$ 3.75 Bn achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade generated US$ 659 Mn in 2020.

U.S. Food and Drug Administration (FDA) approved a biosimilar of Remicade called “Avsola” in December 2019, and are now eligible for producing biologics product all over the world.

Increasing demand for biosimilar antibodies in treatment of rheumatoid arthritis along with high patient acceptance rate will boost the market growth.

One of the leaders in prescription medicines, Pfizer received the EU approval for biosimilar antibody therapeutics “Amsparity” for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020.

Elevated new drug approval rates and products in the clinical trials in pharmaceutical companies will drive the market in upcoming years.

Antibodies Market Country-wise Analysis

Why Is U.S Dominating The Global Antibodies Market?

The U.S. is the leading manufacturer of antibodies owing to modern healthcare infrastructural facilities and presence of leading market players in the country. Increasing purchasing power of consumers along with increasing government funding will drive the market growth.

National Health Accounts by Centers for Medicare & Medicaid Services (CMS) in its report states that healthcare spending in U.S. grew by around 4.6% in 2019. Rising cases of cancer and autoimmune diseases in the country will further increase the demand for antibodies.

National Stem Cell Foundation (NSCF) states that, autoimmune diseases are the third most common reason of chronic ailments in U.S. Increasing cases of diabetes and multiple sclerosis in the country will positively influence the demand for antibodies.

In February 2021, U.S. Food and Drug Administration (FDA) issued the authorization for bamlanivimab and etesevimab monoclonal antibodies administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients suffering for SARS-CoV-2 and are succeptible to progressing to severe case. This will accelerate the demand for antibodies in the country for years to come.

What Are The Factors Driving Antibodies Demand In Saudi Arabia?

GCC countries led by Saudi Arabia is emphasizing on early diagnosis and screening of cancer to elevate the survival rate and chance of successful treatment. Increasing screening and diagnosis using biosimilar antibodies therapeutics will bode well with market growth in the region.

Around 1291 new cases of childhood cancer were reported in Saudi Arabia in 2020, as per the report from World Health Organization (WHO). Increasing establishment of biotechnology research and development centers to develop cancer monoclonal antibodies will drive the market growth in upcoming years.

Market Players are working towards developing antibodies which are effective in treating COVID-19. Biotech company SaudiVax and U.S. firm Abound Bio jointly announced a licensing agreement for developing COVID-19 treatment.

The companies discovered a human monoclonal antibodies showcasing high potency in neutralizing activity against SARS-CoV-2. This will create growth opportunities in Saudi Arabia.

How Will Antibodies Market Growth Unfold in China?

World Bank evaluated that the healthcare expenditure in China was accounted for 5.35% of its gross domestic product (GDP) in 2018. Rising geriatric population and associated ailments will drive the market growth in upcoming years.

Development and production of antibodies in China is expected to increase significantly owing to increasing government investment towards drugs development coupled with growing awareness about various medical ailments like rheumatoid arthritis, cancer and infections.

Chine developed its first U.S. Food and Drug Administration (FDA) approved antibody in March 2018.The antibody named “Trogarzo” was useful in treating resistant HIV infections. Similarly more than ten other China made biologics are under clinical trials.

The government also started a “Chinese Antibody Society” with the aim to assist in speedy FDA approval as well as ensure effective marketing of China made antibody-based therapeutics.

These initiatives are expected to reflect positively on the China market, presenting conducive environment for the growth of antibodies sales.

What is Influencing Antibodies Market Growth In India?

Indian antibodies market is anticipated to grow at a rapid pace owing to rising cases of cancer and cardiovascular diseases along with development of healthcare system in the country.

As per the data from Global Cancer Observatory, 1.322 million new cancer cases were registered in India in 2020, while 2.72 million people had cancer for 5 years. Surge in cancer patients will drive the demand for monoclonal antibodies for cancer treatment.

Antibodies are finding its use in developing treatment for ongoing COVID-19 pandemic. World Health Organization has reported that around 29.97 million people were infected with COVID-19 in India as of June 2021. These numbers indicate huge potential for monoclonal antibodies market in India.

In 2021, Roche collaborated with Cipla to provide monoclonal antibody drugs called “REGEN-COV2”. REGEN-COV2 is a cocktail of monoclonal antibodies casirivimab and imdevimab and has received strict medical emergency approval.

Rapid technological advancements, increasing government funding to make the treatment affordable, and increasing consumer spending on healthcare will create opportunities for growth in India.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Antibodies Market Category-wise Insights

Why Are Cancer Antibodies Gaining Popularity?

Rising prevalence of non-Hodgkin lymphoma and other type of cancer has fuelled the demand for cancer antibodies for developing noninvasive and safe treatment options. With focus on cancer research increasing, the antibodies market outlook for the upcoming decade will remain positive.

Which Product Will Register High Demand?

Monoclonal antibodies are predicted to showcase elevated demand throughout the forecast period owing to rising drug approval rates. Besides this, sales in this category will rise in response to the increasing cases of rheumatoid arthritis, psoriasis, and asthma in geriatric population across the globe. The rising demand for effective treatment of aforementioned chronic ailments will remain a chief growth driver in this category.

Who is the Leading End User of Antibodies?

Hospitals are expected to generate highest demand throughout the forecast period. Growing pool of patients and faster accessibility to healthcare will elevate the demand in Hospitals.

Hospitals around the world register a higher footfall of patients as they offer expert care and infrastructure required for administering necessary treatment. Antibodies demand in hospitals multiplied amid COVID-19 outbreak.

Even as governments roll out vaccination drives to contain the pandemic, hospitals will remain dominant end user on account of rising cases of various types of chronic ailments.

Antibodies Market - Competitive Landscape

Future Market Insights (FMI) has found that market players are working towards developing new antibodies to treat cancer and other diseases. They are also researching to create long acting antibody drugs to reduce healthcare cost.

In order to gain a competitive edge in the antibodies market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic merger and acquisition for portfolio expansion is in the cards as well.

On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment “iptacopan”, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that, during 12 weeks of iptacopan monotherapy treatment no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.

In August 2020, Johnson & Johnson entered into final agreement to acquire Momenta Pharmaceuticals Inc. for around US$ 6.5 Bn. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.

The acquisition will allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth through expansion into autoantibody-driven disease.

Antibodies Market – Report Scope

Attribute	Details
Forecast Period	2021 – 2031
Historical Data Available for	2016 – 2026
Market Analysis	US$ Mn for Value & Units for Volume
Key Countries Covered	US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa
Key Segments Covered	By Disease Indication, End user, Product Type, Region
Key Companies Profiled	Novartis AG F. Hoffmann-La Roche AG Johnson & Johnson Takeda Pharmaceutical Company Limited Amgen Inc. Biogen Inc. Bristol-Myers Squibb Company AbbVie Inc. Sanofi SA Eli Lilly and Co.
Report Coverage	Market Overview, Market Background, Market Forecast, Segmental Analysis, Regional Profiling and Competition Analysis
Customization & Pricing	Available upon Request

Key Segments Covered in Antibodies Market Study

By Disease Indication

Cardiovascular diseases
CNS disorders
Cancer
Autoimmune Disorders

By Product Type

Monoclonal antibodies
Polyclonal antibodies
Antibody-drug complexes (ADCs)

By End User

Hospitals
Long-term Care Facilities
Research institutes

By Region

North America
Latin America
Western Europe
Eastern Europe
Asia Pacific excluding Japan
Japan
Middle East and Africa (MEA)

1. Executive Summary

2. Assumptions and Acronyms

3. Research Methodology

4. Antibodies Market Overview

4.1. Introduction

4.1.1. Antibodies Market Definition

4.1.2. Antibodies Market Taxonomy

4.1.3. Antibodies Market Product Type Overview

4.1.4. Overview

4.2. Antibodies Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunity

4.3. Regulations

5. Global Antibodies Market Forecast

5.1. Market Value (US$ Mn) Forecast

5.1.1. Y-o-Y Growth Projections

5.1.2. Absolute $ Opportunity

5.2. Antibodies Market Trends

5.2.1. Market Share, By Region

5.2.2. Market Share, By Product Type

5.2.3. Market Share, By End User

5.2.4. Market Share, By Disease Indication

6. Global Antibodies Market Analysis, By Product Type

6.1. Introduction

6.1.1. Y-o-Y Growth Comparison, By Product Type

6.1.2. Market Share & Basis Point (BPS) Analysis, By Product Type

6.2. Market Forecast, By Product Type

6.2.1. Monoclonal antibodies

6.2.1.1. Absolute $ Opportunity

6.2.1.2. Market Value (US$ Mn) Forecast

6.2.2. Polyclonal antibodies

6.2.2.1. Absolute $ Opportunity

6.2.2.2. Market Value (US$ Mn) Forecast

6.2.3. Antibody-drug complexes (ADCs)

6.2.3.1. Absolute $ Opportunity

6.2.3.2. Market Value (US$ Mn) Forecast

6.2.4. Market Attractiveness Analysis, By Product Type

6.2.5. Prominent Trends

7. Global Antibodies Market Analysis, By Disease Indication

7.1. Introduction

7.1.1. Y-o-Y Growth Comparison, By Disease Indication

7.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication

7.2. Market Forecast, By Disease Indication

7.2.1. Cardiovascular diseases

7.2.1.1. Absolute $ Opportunity

7.2.1.2. Market Value (US$ Mn) Forecast

7.2.2. CNS disorders

7.2.2.1. Absolute $ Opportunity

7.2.2.2. Market Value (US$ Mn) Forecast

7.2.3. Cancer

7.2.3.1. Absolute $ Opportunity

7.2.3.2. Market Value (US$ Mn) Forecast

7.2.4. Autoimmune Disorders

7.2.4.1. Absolute $ Opportunity

7.2.4.2. Market Value (US$ Mn) Forecast

7.2.5. Market Attractiveness Analysis, By Disease Indication

7.2.6. Prominent Trends

8. Global Antibodies Market Analysis, By End User

8.1. Introduction

8.1.1. Y-o-Y Growth Comparison, By End User

8.1.2. Market Share & Basis Point (BPS) Analysis, By End User

8.2. Market Forecast, By End User

8.2.1. Hospitals

8.2.1.1. Absolute $ Opportunity

8.2.1.2. Market Value (US$ Mn) Forecast

8.2.2. Long-term Care Facilities

8.2.2.1. Absolute $ Opportunity

8.2.2.2. Market Value (US$ Mn) Forecast

8.2.3. Research institutes

8.2.3.1. Absolute $ Opportunity

8.2.3.2. Market Value (US$ Mn) Forecast

8.2.4. Market Attractiveness Analysis, By End User

8.2.5. Prominent Trends

9. Global Antibodies Market Analysis, By Region

9.1. Introduction

9.1.1. Y-o-Y Growth Projections, By Region

9.1.2. Market Share & Basis Point (BPS) Analysis, By Region

9.2. Market Forecast, By Region

9.2.1. North America Market Value (US$ Mn) Forecast

9.2.2. Latin America Market Value (US$ Mn) Forecast

9.2.3. Western Europe Market Value (US$ Mn) Forecast

9.2.4. Eastern Europe Market Value (US$ Mn) Forecast

9.2.5. Asia Pacific Excl. Japan Market Value (US$ Mn) Forecast

9.2.6. Japan Market Value (US$ Mn) Forecast

9.2.7. MEA Market Value (US$ Mn) Forecast

9.3. Regional Attractiveness Analysis

10. North America Antibodies Market Analysis

10.1. Introduction

10.1.1. Y-o-Y Growth Projections, By Country

10.1.2. Market Share & Basis Point (BPS) Analysis, By Country

10.2. Key Regulations

10.3. Key Trends

10.4. North America Market Forecast

10.4.1. Market Value (US$ Mn) Forecast, By Country

10.4.1.1. S. Absolute $ Opportunity

10.4.1.2. Canada Absolute $ Opportunity

10.4.2. Market Value (US$ Mn) Forecast, By Product Type

10.4.2.1. Monoclonal antibodies

10.4.2.2. Polyclonal antibodies

10.4.2.3. Antibody-drug complexes (ADCs)

10.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

10.4.3.1. Cardiovascular diseases

10.4.3.2. CNS disorders

10.4.3.3. Cancer

10.4.3.4. Autoimmune Disorders

10.4.4. Market Value (US$ Mn) Forecast, By End User

10.4.4.1. Hospitals

10.4.4.2. Long-term Care Facilities

10.4.4.3. Research institutes

10.4.5. Market Attractiveness Analysis

10.4.5.1. By Country

10.4.5.2. By Product Type

10.4.5.3. By End User

10.4.5.4. By Disease Indication

10.4.6. Drivers & Restraints: Impact Analysis

11. Latin America Antibodies Market Analysis

11.1. Introduction

11.1.1. Y-o-Y Growth Projections, By Country

11.1.2. Market Share & Basis Point (BPS) Analysis, By Country

11.2. Key Regulations

11.3. Key Trends

11.4. Latin America Market Forecast

11.4.1. Market Value (US$ Mn) Forecast, By Country

11.4.1.1. Argentina Absolute $ Opportunity

11.4.1.2. Brazil Absolute $ Opportunity

11.4.1.3. Mexico Absolute $ Opportunity

11.4.1.4. Rest of Latin America Absolute $ Opportunity

11.4.2. Market Value (US$ Mn) Forecast, By Product Type

11.4.2.1. Monoclonal antibodies

11.4.2.2. Polyclonal antibodies

11.4.2.3. Antibody-drug complexes (ADCs)

11.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

11.4.3.1. Cardiovascular diseases

11.4.3.2. CNS disorders

11.4.3.3. Cancer

11.4.3.4. Autoimmune Disorders

11.4.4. Market Value (US$ Mn) Forecast, By End User

11.4.4.1. Hospitals

11.4.4.2. Long-term Care Facilities

11.4.4.3. Research institutes

11.4.5. Market Attractiveness Analysis

11.4.5.1. By Country

11.4.5.2. By Product Type

11.4.5.3. By End User

11.4.5.4. By Disease Indication

11.4.6. Drivers & Restraints: Impact Analysis

12. Western Europe Antibodies Market Analysis

12.1. Introduction

12.1.1. Y-o-Y Growth Projections, By Country

12.1.2. Market Share & Basis Point (BPS) Analysis, By Country

12.2. Key Regulations

12.3. Key Trends

12.4. Western Europe Market Forecast

12.4.1. Market Value (US$ Mn) Forecast, By Country

12.4.1.1. K. Absolute $ Opportunity

12.4.1.2. Germany Absolute $ Opportunity

12.4.1.3. France Absolute $ Opportunity

12.4.1.4. Spain Absolute $ Opportunity

12.4.1.5. Italy Absolute $ Opportunity

12.4.1.6. Nordic Countries Absolute $ Opportunity

12.4.1.7. Rest of Western Europe Absolute $ Opportunity

12.4.2. Market Value (US$ Mn) Forecast, By Product Type

12.4.2.1. Monoclonal antibodies

12.4.2.2. Polyclonal antibodies

12.4.2.3. Antibody-drug complexes (ADCs)

12.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

12.4.3.1. Cardiovascular diseases

12.4.3.2. CNS disorders

12.4.3.3. Cancer

12.4.3.4. Autoimmune Disorders

12.4.4. Market Value (US$ Mn) Forecast, By End User

12.4.4.1. Hospitals

12.4.4.2. Long-term Care Facilities

12.4.4.3. Research institutes

12.4.5. Market Attractiveness Analysis

12.4.5.1. By Country

12.4.5.2. By Product Type

12.4.5.3. By End User

12.4.5.4. By Disease Indication

12.4.6. Drivers & Restraints: Impact Analysis

13. Eastern Europe Antibodies Market Analysis

13.1. Introduction

13.1.1. Y-o-Y Growth Projections, By Country

13.1.2. Market Share & Basis Point (BPS) Analysis, By Country

13.2. Key Regulations

13.3. Key Trends

13.4. Eastern Europe Market Forecast

13.4.1. Market Value (US$ Mn) Forecast, By Country

13.5. Poland Absolute $ Opportunity

13.6. Russia Absolute $ Opportunity

13.7. Rest of Eastern Europe Absolute $ Opportunity

13.7.1. Market Value (US$ Mn) Forecast, By Product Type

13.7.1.1. Monoclonal antibodies

13.7.1.2. Polyclonal antibodies

13.7.1.3. Antibody-drug complexes (ADCs)

13.7.2. Market Value (US$ Mn) Forecast, By Disease Indication

13.7.2.1. Cardiovascular diseases

13.7.2.2. CNS disorders

13.7.2.3. Cancer

13.7.2.4. Autoimmune Disorders

13.7.3. Market Value (US$ Mn) Forecast, By End User

13.7.3.1. Hospitals

13.7.3.2. Long-term Care Facilities

13.7.3.3. Research institutes

13.7.4. Market Attractiveness Analysis

13.7.4.1. By Country

13.7.4.2. By Product Type

13.7.4.3. By End User

13.7.4.4. By Disease Indication

13.7.5. Drivers & Restraints: Impact Analysis

14. Asia Pacific Excl. Japan Antibodies Market Analysis

14.1. Introduction

14.1.1. Y-o-Y Growth Projections, By Country

14.1.2. Market Share & Basis Point (BPS) Analysis, By Country

14.2. Key Regulations

14.3. Key Trends

14.4. Asia Pacific Excl. Japan Market Forecast

14.4.1. Market Value (US$ Mn) Forecast, By Country

14.4.1.1. China Absolute $ Opportunity

14.4.1.2. India Absolute $ Opportunity

14.4.1.3. ASEAN Absolute $ Opportunity

14.4.1.4. Australia & New Zealand Absolute $ Opportunity

14.4.1.5. Rest of APEJ Absolute $ Opportunity

14.4.2. Market Value (US$ Mn) Forecast, By Product Type

14.4.2.1. Monoclonal antibodies

14.4.2.2. Polyclonal antibodies

14.4.2.3. Antibody-drug complexes (ADCs)

14.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

14.4.3.1. Cardiovascular diseases

14.4.3.2. CNS disorders

14.4.3.3. Cancer

14.4.3.4. Autoimmune Disorders

14.4.4. Market Value (US$ Mn) Forecast, By End User

14.4.4.1. Hospitals

14.4.4.2. Long-term Care Facilities

14.4.4.3. Research institutes

14.4.5. Market Attractiveness Analysis

14.4.5.1. By Country

14.4.5.2. By Product Type

14.4.5.3. By End User

14.4.5.4. By Disease Indication

14.4.6. Drivers & Restraints: Impact Analysis

15. Japan Antibodies Market Analysis

15.1. Introduction

15.2. Key Regulations

15.3. Key Trends

15.4. Japan Market Forecast

15.4.1. Market Value (US$ Mn) Forecast, By Product Type

15.4.1.1. Monoclonal antibodies

15.4.1.2. Polyclonal antibodies

15.4.1.3. Antibody-drug complexes (ADCs)

15.4.2. Market Value (US$ Mn) Forecast, By Disease Indication

15.4.2.1. Cardiovascular diseases

15.4.2.2. CNS disorders

15.4.2.3. Cancer

15.4.2.4. Autoimmune Disorders

15.4.3. Market Value (US$ Mn) Forecast, By End User

15.4.3.1. Hospitals

15.4.3.2. Long-term Care Facilities

15.4.3.3. Research institutes

15.4.4. Market Attractiveness Analysis

15.4.4.1. By Product Type

15.4.4.2. By End User

15.4.4.3. By Disease Indication

15.4.5. Drivers & Restraints: Impact Analysis

16. MEA Antibodies Market Analysis

16.1. Introduction

16.1.1. Y-o-Y Growth Projections, By Country

16.1.2. Market Share & Basis Point (BPS) Analysis, By Country

16.2. Key Regulations

16.3. Key Trends

16.4. MEA Market Forecast

16.4.1. Market Value (US$ Mn) Forecast, By Country

16.4.1.1. GCC Countries Absolute $ Opportunity

16.4.1.2. South Africa Absolute $ Opportunity

16.4.1.3. North Africa Absolute $ Opportunity

16.4.1.4. Rest of MEA Absolute $ Opportunity

16.4.2. Market Value (US$ Mn) Forecast, By Product Type

16.4.2.1. Monoclonal antibodies

16.4.2.2. Polyclonal antibodies

16.4.2.3. Antibody-drug complexes (ADCs)

16.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

16.4.3.1. Cardiovascular diseases

16.4.3.2. CNS disorders

16.4.3.3. Cancer

16.4.3.4. Autoimmune Disorders

16.4.4. Market Value (US$ Mn) Forecast, By End User

16.4.4.1. Hospitals

16.4.4.2. Long-term Care Facilities

16.4.4.3. Research institutes

16.4.5. Market Attractiveness Analysis

16.4.5.1. By Country

16.4.5.2. By Product Type

16.4.5.3. By End User

16.4.5.4. By Disease Indication

16.4.6. Drivers & Restraints: Impact Analysis

17. Competition Landscape

17.1. Company Share Analysis

17.2. Competition Dashboard

17.3. Company Profiles Inclusions

17.3.1. Revenue

17.3.2. Products/Brand Offerings

17.3.3. Key developments

17.3.4. SWOT Analysis

17.4. Company Profiled

17.4.1. Novartis AG

17.4.2. Hoffmann-La Roche Ltd.

17.4.3. Johnson & Johnson Services, Inc.

17.4.4. Takeda Pharmaceutical Company Limited

17.4.5. Amgen Inc.

17.4.6. Biogen Inc.

17.4.7. Bristol-Myers Squibb Company

17.4.8. AbbVie Inc.

17.4.9. Sanofi

17.4.10. Eli Lilly and Co.

Customize this Report

Let us know your requirement to get
100% FREE customization

Customize Now

List of Tables

Global Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Global Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Global Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Global Antibodies Market Value (US$ Mn) Analysis and Forecast By Region, 2021 – 2031
North America Antibodies Market Value (US$ Mn) Forecast By Country, 2021 – 2031
North America Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
North America Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
North America Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Latin America Antibodies Market Value (US$ Mn) Forecast By Country, 2021 – 2031
Latin America Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Latin America Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Latin America Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Western Europe Antibodies Market Value (US$ Bn) Forecast By Country, 2021 – 2031
Western Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Western Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Western Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Eastern Europe Antibodies Market Value (US$ Mn) Forecast By Country, 2021 – 2031
Eastern Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Eastern Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Eastern Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
APEJ Antibodies Market Value (US$ Mn) Forecast By Country, 2021 – 2031
APEJ Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031 APEJ Antibodies Market BPS Analysis, Market
APEJ Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Japan Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
Japan Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
Japan Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
MEA Antibodies Market Value (US$ Mn) Forecast By Country, 2021 – 2031
MEA Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
MEA Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
MEA Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Global Antibody Market Split By Drug Type (2021)
Global Antibody Market Split By Disease Indication (2021)
Global Antibody Market Split By End User (2021)
Global Antibody Market Split By By Region (2021)
Global Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
Global Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
Global Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Monoclonal Antibodies Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Polyclonal Antibodies Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Antibody-drug Complexes (ADC) Drug Type Segment, 2021 – 2031
Global Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
Global Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
Global Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Hospitals Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Long-term Care Facilities Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Research Institutes Drug Type Segment, 2021 – 2031
Global Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
Global Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
Global Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By CNS Disorders Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Cardiovascular Diseases Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Mn) By Cancer Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Autoimmune Disorders Segment, 2021 – 2031
Global Antibodies Market BPS Analysis (%) By Region, 2021 & 2031
Global Antibodies Market Attractiveness Analysis By Region, 2021 – 2031
Global Antibodies Market Y-o-Y growth (%) By Region, 2021 – 2031
North America Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Latin America Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Global Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
Global Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
Global Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Monoclonal Antibodies Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Polyclonal Antibodies Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Antibody-drug Complexes (ADC) Drug Type Segment, 2021 – 2031
Global Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
Global Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
Global Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Hospitals Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Long-term Care Facilities Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Research Institutes Drug Type Segment, 2021 – 2031
Global Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
Global Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
Global Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By CNS Disorders Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Cardiovascular Diseases Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Mn) By Cancer Segment, 2021 – 2031
Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Autoimmune Disorders Segment, 2021 – 2031
Global Antibodies Market BPS Analysis (%) By Region, 2021 & 2031
Global Antibodies Market Attractiveness Analysis By Region, 2021 – 2031
Global Antibodies Market Y-o-Y growth (%) By Region, 2021 – 2031
North America Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Latin America Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Western Europe Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Eastern Europe Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
APEJ Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
Japan Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
MEA Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
North America Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
North America Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
North America Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
North America Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
North America Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
North America Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
North America Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
North America Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
North America Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
North America Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
North America Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
North America Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
Latin America Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
Latin America Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
Latin America Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
Latin America Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
Latin America Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
Latin America Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Latin America Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
Latin America Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
Latin America Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
Latin America Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
Latin America Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
Latin America Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
Western Europe Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
Western Europe Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
Western Europe Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
Western Europe Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
Western Europe Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
Western Europe Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Western Europe Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
Western Europe Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
Western Europe Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
Western Europe Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
Western Europe Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
Western Europe Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
Eastern Europe Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
Eastern Europe Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
Eastern Europe Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
Eastern Europe Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
Eastern Europe Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
Eastern Europe Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Eastern Europe Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
Eastern Europe Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
Eastern Europe Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
Eastern Europe Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
Eastern Europe Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
Eastern Europe Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
APEJ Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
APEJ Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
APEJ Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
APEJ Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
APEJ Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
APEJ Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
APEJ Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
APEJ Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
APEJ Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
Japan Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
Japan Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
Japan Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
Japan Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
Japan Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
Japan Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
Japan Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
Japan Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
Japan Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
MEA Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
MEA Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
MEA Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
MEA Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
MEA Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
MEA Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
MEA Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
MEA Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
MEA Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
MEA Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
MEA Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
MEA Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031